After closing the gap on new hires, FDA could face an exodus of top regulators
The FDA is looking to strengthen its workforce using new authorities granted under the 21st Century Cures Act, according to a report sent to Congress earlier this month. And they’ll need all the help they can get.
After digging in and reducing the number of open jobs in the past year, FDA leaders say that 40% of senior execs will be eligible to retire next year — leaving the agency susceptible to a major top-level transition period at a time the hunt for top talent has never been more intense.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
